Drug Profile
VM 3500
Alternative Names: VM-3500Latest Information Update: 21 Jun 2022
Price :
$50
*
At a glance
- Originator Viriom
- Class Antivirals
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV-1 infections
Most Recent Events
- 21 Jun 2022 VM 3500 is still in preclinical development for HIV-1 infections in Russia (Viriom pipeline, June 2022)
- 28 Apr 2021 No recent reports of development identified for preclinical development in HIV-1 infections in Russia
- 02 Jul 2019 Viriom enters into a licensing agreement with Lloyds Pharma for elsulfavirine and other drugs from Viriom HIV and Hepatitis B portfolio in Indonesia